SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

MARKHAM, IN / ACCESS CABLE / July 21, 2022 / iFabric Corp. (“iFabric” or the “Company”) (TSX:IFA)(OTCQX:IFABF), today provides an update on its clinical trial of medical garments (i.e., “medical clothing”) treated with the antimicrobial ProTX2 and the Company’s REPELTX water. -Repellent technologies.

“I am pleased to report that phase one of our trial has now been completed,” said Hylton Karon, President and CEO of iFabric.

Sponsored Content:

“Our trial was conducted at MemorialCare Medical Group – Irvine, in the United States,” added Mr. Karon.

“The trial consisted of scrubs delivered in three forms: one treated with our ProTX2 antimicrobial technology, one with a combination of ProTX2 and RepelTX (durable water repellent technology), and a third (control) group of untreated scrubs. The trial comprised 125 nurses contracted for 3 shifts per nurse, equating to a total of 375 regular staff shifts. At the beginning of each shift, nurses received new, unmarked scrubs from one of three groups, which were rubbed down twice, once before the start of the shift and a second time at the end of the shift. The primary endpoint of the assay is to compare bacterial loads in washes treated with our technologies compared to untreated washes. Reducing the pathogen load is key to improving the protection of the user and those they encounter during their working day. The spread of infection by surface contact is a major concern in the healthcare industry.

“The trial now moves into its second, laboratory-based phase, which involves testing for bacterial loads. Once all the laboratory tests are completed, the third step will be to analyze the data against a set of criteria established before the trial. The fourth and final step will be to provide our analyzes to a recognized peer-reviewed medical journal. revision and publication. Further updates will be provided as the trial progresses through the remaining phases,” concluded Hylton Karon.


Sponsored Content: is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping

ProTX2® is a powerful green technology that provides antibacterial, antimicrobial, anti-mold, anti-fungal and anti-odor protection. When treated, each textile fiber is fundamentally transformed through PROTX2® technology, providing unmatched patented protection against pathogens associated with healthcare-associated infections, as well as the strongest odours, for healthcare and medical textiles. high performance.


RepelTX is the next generation in sustainable water repellency performance. RepelTX modifies fabric at the molecular level by permanently adhering hydrophobic “hairs” to individual fibers that lift liquids, causing them to bead and detach from the fabric surface.

ABOUT iFabric Corp:

Headquartered in Markham, Ontario, iFabric,, is listed on the TSX and currently has 29.7 million shares issued and outstanding. Its two strategic divisions offer a variety of products and services through wholly owned subsidiaries, namely Intelligent Fabric Technologies (North America) Inc. (“IFTNA”) and Coconut Grove Pads Inc. (“Coconut Grove”).

IFTNA focuses on the development and sale of high-performance sports apparel, medical protective apparel, consumer protective apparel, and proprietary treatments that provide “smart” properties to fabrics, foams, plastics, and many other surfaces, thereby improving the safety and well-being. be of the user. Such smart properties include antiviral and antibacterial features, water repellency and UV protection, among others.

Coconut Grove, doing business as Coconut Grove Intimates, is a designer, manufacturer, distributor, licensor and licensee of women’s intimate apparel products and accessories.

For more information contact:

Hilton Price, CFO
Phone: 647.465.6161
Email: [email protected]

Investor Relations:
Renmark Financial Services
Steve Hossein
Phone: 514.939.3989
Email: [email protected]

FONT: iFabric Corp

See source version at access

Source link

Leave a Reply

Your email address will not be published.